Use of Resmetirom in Patients With Metabolic Dysfunction-Associated Steatohepatitis

G&H Why was there a need to develop a therapeutic approach for metabolic dysfunction-associated steatohepatitis? SH Between 30% and 40% of individuals in the United States […]

Update on Treatment for Metabolic Dysfunction-Associated Steatohepatitis Cirrhosis

G&H What is the likelihood that a patient with metabolic dysfunction-associated steatohepatitis has cirrhosis? WA The likelihood of cirrhosis depends on which patients with metabolic dysfunction-associated […]

Examining the Nomenclature Change From NAFLD and NASH to MASLD and MASH

G&H Why was the nomenclature for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis changed? MR From a historical perspective, the terms nonalcoholic fatty liver disease (NAFLD) […]